News
Broad access to the fruits of NIH’s investments—whether in the form of data, results, or products—drives innovation. To advance this aim, NIH is launching a new policy to improve access to medical products developed from NIH-owned inventions. This policy emphasizes the importance of proactive
Register to attend a free webinar to assess co-developing an NCI technology. Attendees will learn about new antibodies developed at the National Cancer Institute in the laboratory of David Fitzgerald, Ph.D. Dr. Fitzgerald and his team established that using one of the antibodies, 40H3, as an
Inventors at the National Human Genome Research Institute (NHGRI) discovered that N-acetylmannosamine (ManNAc) can be used for therapeutic purposes. ManNAc therapy given orally shows long-term safety and biochemical efficacy. ManNAc is a small uncharged physiological molecule that crosses membranes
NIH has 1,200 scientists in the Intramural Research Program who research and develop new drugs, vaccines, methods, and other products to better public health. These scientists become inventors when their research results in a licensable material or product. The NIH Record sat down with Dr. Niraj